左心室辅助装置植入患者三尖瓣反流的外科治疗:TVVAD试验中期分析
TVVAD试验中期分析纳入60例术前中重度三尖瓣反流的左心室辅助装置植入患者,随机分为同期三尖瓣手术组(n=32)与不手术组(n=28)。6个月内中重度右心衰竭发生率两组相似(46.9% vs 50%,P=.81),三尖瓣手术有效减少三尖瓣反流但未降低右心衰竭发生率。
要点
- 左心室辅助装置植入前显著三尖瓣反流者术后6个月内右心衰竭发生率高。
- 同期三尖瓣手术较不手术更常使随访超声三尖瓣反流为轻度或无。
- 两组6个月中重度右心衰竭发生率相似(46.9% vs 50%,P=.81)。
核心结论
- 左心室辅助装置植入前存在显著三尖瓣反流与术后6个月内右心衰竭高发生率相关。
- 同期三尖瓣手术成功减少植入后三尖瓣反流,但未降低右心衰竭发生率。
研究设计与样本
- TVVAD试验为随机对照试验,按术前右心室功能障碍分层随机。
- 纳入术前超声心动图中重度三尖瓣反流患者,随机接受单纯左心室辅助装置植入(不进行三尖瓣手术)或同期三尖瓣手术。
- 本报告为前60例随机患者的中期分析,三尖瓣手术组n=32,不手术组n=28。
主要发现
- 随访超声心动图显示三尖瓣手术组(n=32)较不手术组(n=28)更常为轻度或无三尖瓣反流。
- 6个月时中重度右心衰竭发生率三尖瓣手术组46.9% vs 不手术组50%(P=.81)。
- 两组术后死亡率及需要右心室辅助装置方面无显著差异。
- 功能状态及不良事件等次要终点亦无显著差异。
局限性
- 本报告为前60例随机患者的中期分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Right heart failure remains a serious complication of left ventricular assist device therapy. Many patients presenting for left ventricular assist device implantation have significant tricuspid regurgitation. It remains unknown whether concurrent tricuspid valve surgery reduces postoperative right heart failure. The primary aim was to identify whether concurrent tricuspid valve surgery reduced the incidence of moderate or severe right heart failure within the first 6 months after left ventricular assist device implantation. METHODS: Patients with moderate or severe tricuspid regurgitation on preoperative echocardiography were randomized to left ventricular assist device implantation alone (no tricuspid valve surgery) or with concurrent tricuspid valve surgery. Randomization was stratified by preoperative right ventricular dysfunction. The primary end point was the frequency of moderate or severe right heart failure within 6 months after surgery. RESULTS: This report describes a planned interim analysis of the first 60 randomized patients. The tricuspid valve surgery group (n = 32) had mild or no tricuspid regurgitation more frequently on follow-up echocardiography studies compared with the no tricuspid valve surgery group (n = 28). However, at 6 months, the incidence of moderate and severe right heart failure was similar in each group (tricuspid valve surgery: 46.9% vs no tricuspid valve surgery: 50%, P = .81). There was no significant difference in postoperative mortality or requirement for right ventricular assist device between the groups. There were also no significant differences in secondary end points of functional status and adverse events. CONCLUSIONS: The presence of significant tricuspid regurgitation before left ventricular assist device is associated with a high incidence of right heart failure within the first 6 months after surgery. Tricuspid valve surgery was successful in reducing postimplant tricuspid regurgitation compared with no tricuspid valve surgery but was not associated with a lower incidence of right heart failure.
引用
- Mendiola Pla M, Chiang Y, Nicoara A, et al. Surgical Treatment of Tricuspid Valve Regurgitation in Patients Undergoing Left Ventricular Assist Device Implantation: Interim analysis of the TVVAD trial. J Thorac Cardiovasc Surg. 2022. PMID: 36639288. doi:10.1016/j.jtcvs.2022.10.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。